Generic pharmaceutical price decay

Last updated

Generic pharmaceutical price decay is what happens (in the UK) once the originator brand has lost its patent exclusivity (patent expiry) and generic versions of the originator brand have been launched. [1] [2] [3] [4] [5] [6]

Contents

Simple 'scalloped curve' generic price decline Cetirizine tabs 10mg 28 generic pharma price decay decline in the uk after patent expiry.jpg
Simple 'scalloped curve' generic price decline

The number of license holders entering the market is controlled by the ease of manufacture and the number of companies making the active pharmaceutical ingredient (API). For many easy-to-manufacture solid dose tablets and capsules the manufacturing is done in India and China as the costs of production in these countries is significantly lower than in the US or Europe. [7]

On day one of generic launch the first to market the generic product usually gets more market share than late entrants. Both manufacturers (who make their own generic products) and license only holders (who use other companies to do the manufacturing) may be represented. [8]

If only one company is able to release a generic product into the UK market, the discount against the originator brand is likely to be small, and the price will usually follow the same trend as the brand price. However, in most cases more than one company will release stock at launch and they will compete for market share with other manufacturers and license holders. This means persuading chemists and dispensing doctors to purchase stock. [9]

Examples showing the variability of generic price decline Terazosin nicardipine omeprazole ciprofloxacin and pravastatin generic pharma price decay in the uk after patent expiry.jpg
Examples showing the variability of generic price decline

As competition drives the price of the generic product down, the average price in the market typically follows a scalloped curve which will decline with time at a rate that is driven by the numbers of license holders and manufacturers. [10] [11]

Changes in the reimbursement price drug tariff will also serve to suppress this curve even more. [12] [13] [14] [15]

Generic substitution was planned for the England, but this was rejected in late 2010. Generic substitution would have meant that a prescription written for a branded product by a doctor would result in a pharmacist giving the patient a generic medicine. On Thursday 14 October, the UK's Department of Health announced that it would not be proceeding with the proposals to implement generic substitution. Patient safety was cited as the primary reason for the rejection of this policy. [16]

In the case of more complex products, such as creams, inhalers and injectables, generic prices decay at a slower rate as fewer companies are able to make the product. [17]

In the UK, the M category of the drug tariff (reimbursement prices) is used to control the profits of chemists and to reduce the UK's health care tax burden. [18] [19] [20]

The rate of decay of most generic solid dose products has been shown to follow a predictable path and to have some similarity to the decay in price of other non pharmaceutical products. [21] [22]

Eventually price decline comes to and end and the price flattens out at approximately 20% of the original brand price.

Bounces

In about 20% of cases, the average price declines to a low point some months or years after generic launch, and then rises temporarily or bounces (Dead Cat Bounce) [23] These bounces may then initiate the onset of longer term seasonality or recurrent annual price rises. [24]

Bounces happen when the average selling price falls below a license holder's manufacturing cost, making the product unprofitable. License holders and manufacturers then withdraw from the market, reducing the amount of competition and allowing the price to rise. They may later re-enter the market when higher prices make the product profitable once more. This usually forces the average price down again to levels lower than that seen before the start of the bounce.

Seasonality and price bounces Seasonality and price bounces in generic pharmaceutical prices in the years after loss of exclusivity and generic launch.jpg
Seasonality and price bounces
Simple example of a generic drug price bounce Omeprazole caps 20mg 28 generic pharma price decay and price bounce plus drug tariff reimbursement price in the uk after patent expiry.jpg
Simple example of a generic drug price bounce

The reasoning behind why some products bounce whereas others do not, is thought to lie in the rapidity of the initial price decline. In these cases manufacturers and license holders either were not able to or did not forecast the levels to which the price might drop. The period during which their product would be profitable was therefore not known, and the decline into unprofitably left them with stock which could only be sold at a loss. Additionally the product's expiry date might mean that it could not be stored until market prices recovered.

Generic manufacturers and license holders believe that the seasonality induced by these bounces may be related to the time taken to manufacture a new product and gain market access (get the medicines onto chemist's shelves in the relevant country). The period between the high price peaks in the seasonality induced by price bounces has been shown to be approximately two years. [25]

It is possible for a product's price to be affected by seasonality in the absence of price bounces. This seasonality is caused by periods of intense competition in the UK market, and periods of calm with much less competition. In the UK traditionally employees have taken holidays in April, August and January. This is caused by religious holidays like Christmas and Easter, and by spring, summer and winter school holidays.

During holidays, wholesalers, license holders and manufacturers are less competitive than when employees are back at work. During the months when the majority of employees are at work, competing companies continually watch each other's prices and change their own selling prices on a daily or even hourly basis so as to maximize sales and profits.

The pricing trends of some products are believed to be affected by disease patterns, such as the hay fever season in May and winter flu in November. It is also possible that the exchange rates between relevant currencies may be another factor in controlling generic prices. However the evidence for this is weak. [26]

Equalisation

After loss of exclusivity and generic launch the originator brand normally continues to hold at least some market share as either some doctors continue to prescribe the brand or as the originator equalises sales prices against the generic. [27] [28]

Generic, brand and reimbursement (drug tariff) price decay Generic simvastatin and branded zocor tabs 10mg 28 pharma price decay plus drug tariff in the uk after patent expiry.jpg
Generic, brand and reimbursement (drug tariff) price decay

Branded manufactures may build ongoing contracts with wholesalers so that the brand continues to be dispensed in pharmacies even though the prescriptions are generic. This means that an originator may offer an advantageous price to undercut the generic or parallel import. Wholesalers gets a price and supply guarantee in exchange for taking the risk that they may be paying too much in the long term.

Some companies offer 'branded generics' in the UK market. However, these are no longer common, and are not popular as their reimbursement price may be higher than the generic reimbursement price, costing the tax-payer more than a true generic. [29] [30]

Because the generic launch price is often at or close to the originator brand price, more profit can be made in the months following generic launch than in the months later in the product's life cycle. [31] [32] [33]

Patents

Generic launch can only occur once all the patents on the originator brand have expired. These may include both product and process patents, and most products can get a further two years of patent life with a SPC supplementary protection certificate and a few may get a further six months with a pediatric extension.

Related Research Articles

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

Prescription drug list prices in the United States continually are among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and other medical conditions.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

Test data exclusivity refers to protection of clinical trial data required to be submitted to a regulatory agency to prove safety and efficacy of a new drug, and prevention of generic drug manufacturers from relying on this data in their own applications. It provides a form of market exclusivity outside that provided by patent rights.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Pharmaceutical policy is a branch of health policy that deals with the development, provision and use of medications within a health care system. It embraces drugs, biologics, vaccines and natural health products.

Evergreening is any of various legal, business, and technological strategies by which producers extend the lifetime of their patents that are about to expire in order to retain revenues from them. Often the practice includes taking out new patents, or by buying out or frustrating competitors, for longer periods of time than would normally be permissible under the law. Robin Feldman, a law professor at UC Law SF and a leading researcher in intellectual property and patents, defines evergreening as "artificially extending the life of a patent or other exclusivity by obtaining additional protections to extend the monopoly period."

<span class="mw-page-title-main">Glenmark Pharmaceuticals</span> Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

The cost of HIV treatment is a complicated issue with an extremely wide range of costs due to varying factors such as the type of antiretroviral therapy and the country in which the treatment is administered. The first line therapy of HIV, or the initial antiretroviral drug regimen for an HIV-infected patient, is generally cheaper than subsequent second-line or third-line therapies. There is also a great variability of drug prices among low, middle, and high income countries. In general, low-income countries have the lowest cost of antiretroviral therapy, while middle- and high-income tend to have considerably higher costs. Certain prices of HIV drugs may be high and difficult to afford due to patent barriers on antiretroviral drugs and slow regulatory approval for drugs, which may lead to indirect consequences such as greater HIV drug resistance and an increased number of opportunistic infections. Government and activist movements have taken efforts to limit the price of HIV drugs.

<span class="mw-page-title-main">Aspen Pharmacare</span> Major pharmaceutical company in South Africa

Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union.

The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP).

FTC v. Actavis, Inc., 570 U.S. 136 (2013), was a United States Supreme Court decision in which the Court held that the FTC could make an antitrust challenge under the rule of reason against a so-called pay-for-delay agreement, also referred to as a reverse payment patent settlement. Such an agreement is one in which a drug patentee pays another company, ordinarily a generic drug manufacturer, to stay out of the market, thus avoiding generic competition and a challenge to patent validity. The FTC sought to establish a rule that such agreements were presumptively illegal, but the Court ruled only that the FTC could bring a case under more general antitrust principles permitting a defendant to assert justifications for its actions under the rule of reason.

Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.

The British Generic Manufacturers Association is a trade association for the British generic drug industry. It has offices in the City of London.

<span class="mw-page-title-main">Natco Pharma</span> Indian pharmaceutical company

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services. It is a major producer of branded oncology medicines and hepatitis C drugs. The company specialises in producing complex medicines at affordable prices. In 2019, Natco launched its crop health sciences division.

References

  1. ↑ Applied Economics, 2004, 36, 731–73, The price premium of generic to brand-names and pharmaceutical price index, Ying Kon
  2. ↑ NHH Dept. of Economics Discussion Paper No. 39/2007, 6 July 2009, Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment, Kurt R. Brekke, Tor Helge Holmas, Odd Rune Straume
  3. ↑ PDCI Report Series August 2002 Generic Drug Prices: A Canada US Comparison
  4. ↑ PDCI The 2004 Moffatt Prize in Economics, An Analysis on Waxman-Hatch Act: The Effect of Generic Entry on Pharmaceutical Prices, Tracy Chou
  5. ↑ NBER Working Paper No. 3803 (Also Reprint No. r1790), June 1993, Pricing, Patent Loss and the Market For Pharmaceuticals, Richard G. Frank, David S. Salkever
  6. ↑ Journal of Economics & Management Strategy, vol. 6, no. 1, pp. 75-90 Spring 1997, Generic Entry and the Pricing of Pharmaceuticals, Richard G. Frank, David S. Salkever
  7. ↑ JZMed, February 2010, The New Trend of API Sourcing and Contract Manufacturing in China, Jim J. Zhang, Ph.D.
  8. ↑ Journal of Generic Medicines Vol. 8, 1, 28–40, June 2011, The Role of authorized generics in the prescription drug marketplace, Natalia Shcherbakova, Marvin Shepherd, Kenneth Lawson & Kristin Richards
  9. ↑ SANTA CLARA COMPUTER & HIGH TECH. L.J. 489, 509, 2007 ,Do Reverse Payment Settlements Violate the Antitrust Laws?, Christopher M. Holman
  10. ↑ Generics Bulletin 8 Sept 2006 Guessing at prices means losing money
  11. ↑ Generics Bulletin 28 May 2010 Price falls are following a familiar pattern
  12. ↑ Generics Bulletin 24 Nov 2006 Tracing prices before and after category M
  13. ↑ Generics Bulletin 17 Apr 2009 Does reimbursement affect price decay?
  14. ↑ U.S. Department of Commerce International Trade Administration, December 2004, Pharmaceutical Price Controls in OECD Countries
  15. ↑ PharmacoEconomics, Volume 28, Number 8, 1 August 2010 , pp. 649-663(15), Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review, Jaume Puig-Junoy
  16. ↑ Inpharm, 15 October 2010, Government drops generic substitution plans
  17. ↑ Generics Bulletin, 22 Sept 2006, Ondansetron prices could decline by 60%
  18. ↑ Pharmaceutical Services Negotiating Committee (PSNC) Category M
  19. ↑ The NHS Business Services Authority (NHSBSA) publishes the English Drug Tariff online and in print each month
  20. ↑ Generics Bulletin, 19 Oct 2007, New tariff forces down pharmacy margins
  21. ↑ Generics Bulletin, 23 Nov 2007, Taking the long view on pricing strategy
  22. ↑ URCH Publishing, 3 August 2009, Forecasting Generic Drug Prices Made Easy
  23. ↑ Generics Bulletin, 16 Feb 2007, Getting to the bottom of ‘bouncing’ price
  24. ↑ Generics Bulletin, 27 Apr 2007, Bounces may be extreme seasonal effects
  25. ↑ Generics Bulletin, 23 Nov 2007, Taking the long view on pricing strategy
  26. ↑ Generics Bulletin, 25 Sept 2009, Weak pound doesn’t mean higher prices
  27. ↑ Generics Bulletin, 20 March 2009, Tracking brand prices against generics
  28. ↑ International Journal of Medical Marketing Vol. 4, 1 65–73, 7 August 2003, Innovative marketing strategies after patent expiry: The case of GSK’s antibiotic Clamoxyl in France, Pierre Chandon
  29. ↑ BMJ, 27 June 2010, Generic substation could cost money unless reimbursement system is reformed, Martin G Duerden
  30. ↑ Managerial and Decision Economics, 28: 251–265, 17 AUG 2007 'Branded Generics’ as a strategy to limit cannibalization of pharmaceutical markets, David Reiffen and Michael R. Ward
  31. ↑ Generics Bulletin, 14 March 2008, Making more profit soon after launch
  32. ↑ Harvard Healthcare Policy, 31 May 2011, The Value of Patent Expiration, Michael Chernew, PhD
  33. ↑ National Bureau of Economic Research, 15 Sept 2000, The long shadow of patent expiration, Generic entry and Rx to OCT switches, Berndt, Kyle & Ling
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.